<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38334067</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0377</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Vascular medicine (London, England)</Title><ISOAbbreviation>Vasc Med</ISOAbbreviation></Journal><ArticleTitle>Dysregulated platelet function in patients with postacute sequelae of COVID-19.</ArticleTitle><Pagination><StartPage>125</StartPage><EndPage>134</EndPage><MedlinePgn>125-134</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/1358863X231224383</ELocationID><Abstract><AbstractText Label="BACKGROUND">Postacute sequelae of COVID-19 (PASC), also referred to as "Long COVID", sometimes follows COVID-19, a disease caused by SARS-CoV-2. Although SARS-CoV-2 is well known to promote a prothrombotic state, less is known about the thrombosis risk in PASC. Our objective was to evaluate platelet function and thrombotic potential in patients following recovery from SARS-CoV-2, but with clear symptoms of patients with PASC.</AbstractText><AbstractText Label="METHODS">patients with PASC and matched healthy controls were enrolled in the study on average 15 months after documented SARS-CoV-2 infection. Platelet activation was evaluated by light transmission aggregometry (LTA) and flow cytometry in response to platelet surface receptor agonists. Thrombosis in platelet-deplete plasma was evaluated by Factor Xa activity. A microfluidics system assessed thrombosis in whole blood under shear stress conditions.</AbstractText><AbstractText Label="RESULTS">A mild increase in platelet aggregation in patients with PASC through the thromboxane receptor was observed, and platelet activation through the glycoprotein VI (GPVI) receptor was decreased in patients with PASC compared to age- and sex-matched healthy controls. Thrombosis under shear conditions as well as Factor Xa activity were reduced in patients with PASC. Plasma from patients with PASC was an extremely potent activator of washed, healthy platelets - a phenomenon not observed when stimulating healthy platelets after incubation with plasma from healthy individuals.</AbstractText><AbstractText Label="CONCLUSIONS">patients with PASC show dysregulated responses in platelets and coagulation in plasma, likely caused by a circulating molecule that promotes thrombosis. A hitherto undescribed protective response appears to exist in patients with PASC to counterbalance ongoing thrombosis that is common to SARS-CoV-2 infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aggarwal</LastName><ForeName>Anu</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Tamanna K</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>Section of Vascular Medicine, Department of Cardiovascular Medicine, Heart Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pham</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Section of Vascular Medicine, Department of Cardiovascular Medicine, Heart Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Godwin</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8365-7985</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McIntyre</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scalise</LastName><ForeName>Alliefair</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Section of Vascular Medicine, Department of Cardiovascular Medicine, Heart Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Mina K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Vascular Medicine, Department of Cardiovascular Medicine, Heart Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jennings</LastName><ForeName>Courtney</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Mariya</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Hiijun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Englund</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Cleveland Clinic Foundation, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khorana</LastName><ForeName>Alok A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Svensson</LastName><ForeName>Lars G</ForeName><Initials>LG</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Heart Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapadia</LastName><ForeName>Samir</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Section of Vascular Medicine, Department of Cardiovascular Medicine, Heart Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCrae</LastName><ForeName>Keith R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Vascular Medicine, Department of Cardiovascular Medicine, Heart Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cameron</LastName><ForeName>Scott J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0002-9616-1540</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 HL128856</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 HL156812</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL158669</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL158801</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Vasc Med</MedlineTA><NlmUniqueID>9610930</NlmUniqueID><ISSNLinking>1358-863X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.21.6</RegistryNumber><NameOfSubstance UI="D015951">Factor Xa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>bioRxiv. 2023 Nov 21:2023.06.18.545507. doi: 10.1101/2023.06.18.545507</RefSource><PMID Version="1">38045316</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015951" MajorTopicYN="N">Factor Xa</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001777" MajorTopicYN="N">Blood Coagulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="Y">Thrombosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">long COVID-19</Keyword><Keyword MajorTopicYN="N">platelets</Keyword><Keyword MajorTopicYN="N">thrombosis</Keyword></KeywordList><CoiStatement>Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>9</Day><Hour>5</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38334067</ArticleId><ArticleId IdType="mid">NIHMS1995945</ArticleId><ArticleId IdType="pmc">PMC11164201</ArticleId><ArticleId IdType="doi">10.1177/1358863X231224383</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Oran DP, Topol EJ. The proportion of SARS-CoV-2 infections that are asymptomatic: A systematic review. Ann Intern Med 2021; 174: 655&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7839426</ArticleId><ArticleId IdType="pubmed">33481642</ArticleId></ArticleIdList></Reference><Reference><Citation>Peckham H, de Gruijter NM, Raine C, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun 2020; 11: 6317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7726563</ArticleId><ArticleId IdType="pubmed">33298944</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal U, Bedston S, McCowan C, et al. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: Pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales. Lancet 2022; 400: 1305&#x2013;1320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9560746</ArticleId><ArticleId IdType="pubmed">36244382</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SW, Lee J, Moon SY, et al. Physical activity and the risk of SARS-CoV-2 infection, severe COVID-19 illness and COVID-19 related mortality in South Korea: A nationwide cohort study. Br J Sports Med 2022; 56: 901&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pubmed">34301715</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: A multi-center prospective cohort study. Intensive Care Med 2020; 46: 1089&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7197634</ArticleId><ArticleId IdType="pubmed">32367170</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok FA, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7146714</ArticleId><ArticleId IdType="pubmed">32291094</ArticleId></ArticleIdList></Reference><Reference><Citation>Libby P, Luscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J 2020; 41: 3038&#x2013;3044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7470753</ArticleId><ArticleId IdType="pubmed">32882706</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost 2020; 18: 1747&#x2013;1751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9906332</ArticleId><ArticleId IdType="pubmed">32302448</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H, Raza S, Nowell J, et al. Long covid-mechanisms, risk factors, and management. BMJ 2021; 374: n1648.</Citation><ArticleIdList><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Carfi A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA 2020; 324: 603&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Goertz YMJ, Van Herck M, Delbressine JM, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: The post-COVID-19 syndrome? ERJ Open Res 2020; 6: 00542&#x2013;2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7491255</ArticleId><ArticleId IdType="pubmed">33257910</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: A single-centre longitudinal study. Clin Microbiol Infect 2021; 27: 89&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7510771</ArticleId><ArticleId IdType="pubmed">32979574</ArticleId></ArticleIdList></Reference><Reference><Citation>Teuwen LA, Geldhof V, Pasut A, Carmeliet P. COVID-19: The vasculature unleashed. Nat Rev Immunol 2020; 20: 389&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7240244</ArticleId><ArticleId IdType="pubmed">32439870</ArticleId></ArticleIdList></Reference><Reference><Citation>Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 2020; 18: 1738&#x2013;1742.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9906150</ArticleId><ArticleId IdType="pubmed">32302438</ArticleId></ArticleIdList></Reference><Reference><Citation>Koupenova M, Corkrey HA, Vitseva O, et al. SARS-CoV-2 initiates programmed cell death in platelets. Circ Res 2021; 129: 631&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409903</ArticleId><ArticleId IdType="pubmed">34293929</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel L, Stenzel A, Van Hove C, et al. Outcomes in patients discharged with extended venous thromboembolism prophylaxis after hospitalization with COVID-19. Vasc Med 2023; 28: 331&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10235916</ArticleId><ArticleId IdType="pubmed">37259526</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramacciotti E, Barile Agati L, Calderaro D, et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): An open-label, multicentre, randomised, controlled trial. Lancet 2022; 399: 50&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8673881</ArticleId><ArticleId IdType="pubmed">34921756</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuang L, Huang C, Ning Z, et al. Circulating tumor-associated autoantibodies as novel diagnostic biomarkers in pancreatic adenocarcinoma. Int J Cancer 2023; 152: 1013&#x2013;1024.</Citation><ArticleIdList><ArticleId IdType="pubmed">36274627</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Q, Ye H, Sun G, et al. Human proteome microarray identifies autoantibodies to tumor-associated antigens as serological biomarkers for the diagnosis of hepatocellular carcinoma. Mol Oncol 2023; 17: 887&#x2013;900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10158779</ArticleId><ArticleId IdType="pubmed">36587394</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie X, Tian L, Zhao Y, et al. BACH1-induced ferroptosis drives lymphatic metastasis by repressing the biosynthesis of monounsaturated fatty acids. Cell Death Dis 2023; 14: 48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9860034</ArticleId><ArticleId IdType="pubmed">36670112</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Li J, Zhang X, et al. Autoantibody signatures discovered by HuProt protein microarray to enhance the diagnosis of lung cancer. Clin Immunol 2023; 246: 109206.</Citation><ArticleIdList><ArticleId IdType="pubmed">36528251</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiello S, Gastoldi S, Galbusera M, et al. C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19. Blood Adv 2022; 6: 866&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8945302</ArticleId><ArticleId IdType="pubmed">34852172</ArticleId></ArticleIdList></Reference><Reference><Citation>Charitos P, Heijnen I, Egli A, et al. Functional activity of the complement system in hospitalized COVID-19 patients: A prospective cohort study. Front Immunol 2021; 12: 765330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8581394</ArticleId><ArticleId IdType="pubmed">34777382</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajamanickam A, Nathella PK, Venkataraman A, et al. Levels of complement components in children with acute COVID-19 or multisystem inflammatory syndrome. JAMA Netw Open 2023; 6: e231713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10313152</ArticleId><ArticleId IdType="pubmed">36961465</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron SJ, Mix DS, Ture SK, et al. Hypoxia and ischemia promote a maladaptive platelet phenotype. Arterioscler Thromb Vasc Biol 2018; 38: 1594&#x2013;1606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6023774</ArticleId><ArticleId IdType="pubmed">29724818</ArticleId></ArticleIdList></Reference><Reference><Citation>Soo Kim B, Auerbach DS, Sadhra H, et al. Sex-specific platelet activation through protease-activated receptors reverses in myocardial infarction. Arterioscler Thromb Vasc Biol 2021; 41: 390&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7770120</ArticleId><ArticleId IdType="pubmed">33176447</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon J, Turner GC. The intensifying effect of glucose on the protective action of glycine against the heat-inactivation of complement. J Hyg (Lond) 1955; 53: 335&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2217929</ArticleId><ArticleId IdType="pubmed">13263585</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai HM, Tang Y, Lau ZYH, et al. Antibody stabilization for thermally accelerated deep immunostaining. Nat Methods 2022; 19: 1137&#x2013;1146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9467915</ArticleId><ArticleId IdType="pubmed">36050489</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones FS. The effect of heat on antibodies. J Exp Med 1927; 46: 291&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2131163</ArticleId><ArticleId IdType="pubmed">19869339</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbadawi A, Elgendy IY, Joseph D, et al. Racial differences and in-hospital outcomes among hospitalized patients with COVID-19. J Racial Ethn Health Disparities 2022; 9: 2011&#x2013;2018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8432274</ArticleId><ArticleId IdType="pubmed">34506011</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbadawi A, Elgendy IY, Sahai A, et al. Incidence and outcomes of thrombotic events in symptomatic patients with COVID-19. Arterioscler Thromb Vasc Biol 2021; 41: 545&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7770038</ArticleId><ArticleId IdType="pubmed">32990453</ArticleId></ArticleIdList></Reference><Reference><Citation>Manne BK, Denorme F, Middleton EA, et al. Platelet gene expression and function in patients with COVID-19. Blood 2020; 136: 1317&#x2013;1329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7483430</ArticleId><ArticleId IdType="pubmed">32573711</ArticleId></ArticleIdList></Reference><Reference><Citation>Puhm F, Allaeys I, Lacasse E, et al. Platelet activation by SARS-CoV-2 implicates the release of active tissue factor by infected cells. Blood Adv 2022; 6: 3593&#x2013;3605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9023084</ArticleId><ArticleId IdType="pubmed">35443030</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaid Y, Puhm F, Allaeys I, et al. Platelets can associate with SARS-CoV-2 RNA and are hyperactivated in COVID-19. Circ Res 2020; 127: 1404&#x2013;1418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7641188</ArticleId><ArticleId IdType="pubmed">32938299</ArticleId></ArticleIdList></Reference><Reference><Citation>Petito E, Franco L, Falcinelli E, et al. COVID-19 infection-associated platelet and neutrophil activation is blunted by previous anti-SARS-CoV-2 vaccination. Br J Haematol 2023; 201: 851&#x2013;856.</Citation><ArticleIdList><ArticleId IdType="pubmed">36883298</ArticleId></ArticleIdList></Reference><Reference><Citation>Godwin MD, Aggarwal A, Hilt Z, et al. Sex-dependent effect of platelet nitric oxide: Production and platelet reactivity in healthy individuals. JACC Basic Transl Sci 2022; 7: 14&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8807728</ArticleId><ArticleId IdType="pubmed">35128205</ArticleId></ArticleIdList></Reference><Reference><Citation>Miletich JP, Jackson CM, Majerus PW. Interaction of coagulation factor Xa with human platelets. Proc Natl Acad Sci U S A 1977; 74: 4033&#x2013;4036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC431832</ArticleId><ArticleId IdType="pubmed">333455</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh PN, Biggs R. The role of platelets in intrinsic factor-Xa formation. Br J Haematol 1972; 22: 743&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">5037876</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Tamimi M, Grigoriadis G, Tran H, et al. Coagulation-induced shedding of platelet glycoprotein VI mediated by factor Xa. Blood 2011; 117: 3912&#x2013;3920.</Citation><ArticleIdList><ArticleId IdType="pubmed">21252089</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins-Gon&#xe7;alves R, Campos MM, Palhinha L, et al. Persisting platelet activation and hyperactivity in COVID-19 survivors. Circ Res 2022; 131: 944&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9645447</ArticleId><ArticleId IdType="pubmed">36268747</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraday N, Goldschmidt-Clermont PJ, Bray PF. Gender differences in platelet GPIIb-IIIa activation. Thromb Haemost 1997; 77: 748&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">9134654</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson ML, Morris CP, Betz JF, et al. Impact of severe acute respiratory syndrome coronavirus 2 variants on inpatient clinical outcome. Clin Infect Dis 2023; 76: 1539&#x2013;1549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10411930</ArticleId><ArticleId IdType="pubmed">36528815</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahai A, Bhandari R, Godwin M, et al. Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19. Vasc Med. 2021;26:626&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8137864</ArticleId><ArticleId IdType="pubmed">34010070</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2022;399: 143&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8598213</ArticleId><ArticleId IdType="pubmed">34800427</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger JS, Neal MD, Kornblith LZ, et al.; ACTIV-4a Investigators. Effect of P2Y12 inhibitors on organ support-free survival in critically ill patients hospitalized for COVID-19: A randomized clinical trial. JAMA Netw Open 2023;6:e2314428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10214036</ArticleId><ArticleId IdType="pubmed">37227729</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>